Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma

Modern Pathology

Volumn 26, Issue 4, 2013, Pages 511-522

  Rekhtman, Natasha ^a   Tafe, Laura J ^a,c   Chaft, Jamie E ^a,b   Wang, Lu ^a   Arcila, Maria E ^a   Colanta, Agnes ^a,d   Moreira, Andre L ^a   Zakowski, Maureen F ^a   Travis, William D ^a   Sima, Camelia S ^a   Kris, Mark G ^a,b   Ladanyi, Marc ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^d CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

ALK; DNp63 p40; EGFR; KRAS; large cell carcinoma; TTF 1

Indexed keywords

AKT1 PROTEIN; ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE CATALYTIC SUBUNIT ALPHA; PROTEIN KINASE B; PROTEIN P40; THYROID TRANSCRIPTION FACTOR 1; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; GENE MUTATION; GENE REARRANGEMENT; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; MUTATIONAL ANALYSIS; ONCOGENE N RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PULMONARY LARGE CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, LARGE CELL; CARCINOMA, SQUAMOUS CELL; FEMALE; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84876475175     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.195     Document Type: Article

References (60)

1. Brambilla E, Pugatch B, Geisinger KR, et al. Large cell carcinoma, In: Travis WD, Brambilla E, Müller-Herme-link HK, Harris CC(eds). Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press: Lyon; 2004, pp 45-50.
2. Howlader N, Noone AM, Krapcho M, et al. Seer cancer statistics review, 1975-2008, National Cancer Institute. Bethesda, MD, based on November 2010 SEER data submission, posted to the SEER. http://seer.cancer.gov/csr/1975-2008/2011.
3. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung ade-nocarcinoma. J Thorac Oncol 2011;6:244-285.
4. Churg A. The fine structure of large cell undifferen-tiated carcinoma of the lung. Evidence for its relation to squamous cell carcinomas and adenocarcinomas. Hum Pathol 1978;9:143-156. (Pubitemid 8385141)
5. Horie A, Ohta M. Ultrastructural features of large cell carcinoma of the lung with reference to the prognosis of patients. Hum Pathol 1981;12:423-432. (Pubitemid 11057621)
6. Albain KS, True LD, Golomb HM, et al. Large cell carcinoma of the lung. Ultrastructural differentiation and clinicopathologic correlations. Cancer 1985;56:1618-1623. (Pubitemid 15228512)
7. Yamagata N, Shyr Y, Yanagisawa K, et al. A training-testing approach to the molecular classification of resected non-small cell lung cancer. Clin Cancer Res 2003;9:4695-4704. (Pubitemid 37323271)
8. Hou J, Aerts J, den Hamer B, et al. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One 2010;5:e10312.
9. Takeuchi T, Tomida S, Yatabe Y, et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol 2006;24:1679-1688. (Pubitemid 46622139)
10. Yesner R. Large cell carcinoma of the lung. Semin Diagn Pathol 1985;2:255-269. (Pubitemid 16249166)
11. Terry J, Leung S, Laskin J, et al. Optimal immunohis-tochemical markers for distinguishing lung adenocar-cinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol 2010;34:1805-1811.
12. Rossi G, Marchioni A, Milani M, et al. TTF-1, cytokeratin 7, 34betaE12, and CD56/NCAM immunos-taining in the subclassification of large cell carcinomas of the lung. Am J Clin Pathol 2004;122:884-893. (Pubitemid 39577356)
13. Pardo J, Martinez-Penuela AM, Sola JJ, et al. Large cell carcinoma of the lung: an endangered species? Appl Immunohistochem Mol Morphol 2009;17:383-392.
14. Monica V, Ceppi P, Righi L, et al. Desmocollin-3: a new marker of squamous differentiation in undifferen-tiated large-cell carcinoma of the lung. Mod Pathol 2009;22:709-717.
15. Barbareschi M, Cantaloni C, Del Vescovo V, et al. Heterogeneity of large cell carcinoma of the lung: an immunophenotypic and miRNA-based analysis. Am J Clin Pathol 2011;136:773-782.
16. Conde E, Angulo B, Redondo P, et al. The use of P63 immunohistochemistry for the identification of squamous cell carcinoma of the lung. PLoS One 2010;5:e12209.
17. Au NH, Cheang M, Huntsman DG, et al. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol 2004;204:101-109. (Pubitemid 39214487)
18. Monica V, Scagliotti GV, Ceppi P, et al. Differential thymidylate synthase expression in different variants of large-cell carcinoma of the lung. Clin Cancer Res 2009;15:7547-7552.
19. Rekhtman N, Ang DC, Sima CS, et al. Immuno-histochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol 2011;24:1348-1359.
20. Bishop JA, Teruya-Feldstein J, Westra WH, et al. p40 (DNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol 2012;25:405-415.
21. Pelosi G, Fabbri A, Bianchi F, et al. D(delta)np63 (p40) and thyroid transcription factor-1 (ttf1) immunoreac-tivity upon small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach. J Thor Oncol 2012;7:281-290.
22. Nonaka D. A study of deltaNp63 expression in lung non-small cell carcinomas. Am J Surg Pathol 2012;36:895-899.
23. Righi L, Graziano P, Fornari A, et al. Immunohisto-chemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. Cancer 2011;117:3416-3423.
24. Langer CJ. Individualized therapy for patients with non-small cell lung cancer: emerging trends and challenges. Crit Rev Oncol/Hematol 2012;83:130-144.
25. Rekhtman N, Paik PK, Arcila ME, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 2012;18:1167-1176.
26. Takahashi T, Sonobe M, Kobayashi M, et al. Clinico-pathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 2010;17:889-897.
27. Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 2011;29:3574-3579.
28. Drilon A, Rekhtman N, Ladanyi M, et al. Squamous cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol 2012;13:e418-e426.
29. NCCN Guidelines: Non-Small Cell Lung Cancer Version 2. National Comprehensive Cancer Network FW: PA, 2012.
30. Sugio K, Uramoto H, Ono K, et al. Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer 2006;94:896-903.
31. Sartori G, Cavazza A, Sgambato A, et al. EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors. Am J Clin Pathol 2009;131:478-489.
32. Kwiatkowski DJ, Harpole DH Jr., Godleski J, et al. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. J Clin Oncol 1998;16:2468-2477. (Pubitemid 28309043)
33. Graziano SL, Gamble GP, Newman NB, et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol 1999;17:668-675. (Pubitemid 29075256)
34. Rodenhuis S, Slebos RJ. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 1992;52:2665s-2669ss.
35. Arcila M, Lau C, Nafa K, et al. Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J Mol Diagn 2011;13:64-73.
36. Kang SM, Kang HJ, Shin JH, et al. Identical epidermal growth factor receptor mutations in adenocarcinoma-tous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. Cancer 2007;109:581-587. (Pubitemid 46190967)
37. Toyooka S, Yatabe Y, Tokumo M, et al. Mutations of epidermal growth factor receptor and K-ras genes in adenosquamous carcinoma of the lung. Int J Cancer 2006;118:1588-1590.
38. Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008;14:5731-5734.
39. Travis WD, Rekhtman N. Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing. Semin Respir Crit Care Med 2011;32:22-31.
40. Kris MG, Arcila ME, Lau C, et al. Two year results of LC-MAP: an institutional program to routinely profile tumor specimens for the presence of mutations in targetable pathways in all patients with non-small cell lung cancers. J Thorac Oncol 2011;6:S346-S347.
41. Dacic S, Shuai Y, Yousem S, et al. Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. Mod Pathol 2010;23:159-168.
42. Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008;32:810-827.
43. Ang DC, Zakowski MF, Ladanyi M, et al. Characteristic morphology and immunoprofile of lung adenocarci-noma with kras mutations: propensity for solid growth pattern and correlation with TTF-1 expression. Mod Pathol 2010;23:396A.
44. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011;12:175-180.
45. Vakiani E, Solit DB. KRAS and BRAF: drug targets and predictive biomarkers. J Pathol 2011;223:219-229.
46. Yoshida A, Tsuta K, Nakamura H, et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 2011;35:1226-1234.
47. Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 2011;35:15-25.
48. Pelosi G, Rossi G, Bianchi F, et al. Immunohistochem-istry by means of widely agreed-upon markers (cyto-keratins 5/6 and 7, p63, thyroid transcription factor-1, and Vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens. J Thorac Oncol 2011;6:1039-1049.
49. Tsuta K, Tanabe Y, Yoshida A, et al. Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the lung. J Thorac Oncol 2011;6:1190-1199.
50. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung ade-nocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011;24:653-664.
51. Solis LM, Behrens C, Raso MG, et al. Histologic patterns and molecular characteristics of lung adeno-carcinoma associated with clinical outcome. Cancer 2012;118:2889-2899.
52. Sica G, Yoshizawa A, Sima CS, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol 2010;34:1155-1162.
53. Barlesi F, Pinot D, Legoffic A, et al. Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung. Br J Cancer 2005;93:450-452. (Pubitemid 43080019)
54. Anagnostou VK, Syrigos KN, Bepler G, et al. Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol 2009;27:271-278.
55. Berghmans T, Paesmans M, Mascaux C, et al. Thyroid transcription factor 1-a new prognostic factor in lung cancer: a meta-analysis. Ann Oncol 2006;17:1673-1676. (Pubitemid 44680888)
56. Hammerman PS, Sos ML, Ramos AH, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 2011;1:78-89.
57. Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010;2:62ra93.
58. Paik PK, Hasanovic A, Wang L, et al. Multiplex testing for driver mutations in squamous cell carcinomas of the lung. J Clin Oncol 2012;30(Suppl):abstr 7505.
59. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191. (Pubitemid 41095154)
60. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.